![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
November 16, 2021
Practice-changing trial results in melanoma; Group and committee leadership updates; remembering a dear colleague and friend
November 16, 2021
The phase 3 DREAMseq clinical trial provides strong evidence for starting treatment with combination immunotherapy then giving targeted therapy if the disease progresses in patients with BRAF V600 mutant metastatic melanoma
November 16, 2021
In October, the ECOG-ACRIN Cancer Research Group lost one of its most trusted senior counsellors, Regulatory Officer Robert B. Catalano, PharmD
November 16, 2021
This pilot study is determining the feasibility and acceptability for adult and young adult participants patients between the ages of 18 and 39 in ECOG-ACRIN treatment trials to use the National Institutes of Health’s Patient-Reported Outcomes Measurement Information System (PROMIS®)
November 16, 2021
In an annual evaluation, 30 member networks and programs met rigorous standards established by ECOG-ACRIN to indicate exemplary cancer research
November 16, 2021
This phase II randomized controlled trial is evaluating the effect of adding hydroxychloroquine to treatment with dabrafenib and trametinib in patients with advanced BRAF mutant melanoma
November 16, 2021
A Standing Main Member of ECOG-ACRIN since 1996
November 16, 2021
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more